Suggested remit: To appraise the clinical and cost effectiveness of daprodustat within its marketing authorisation for treating anaemia in adults with chronic kidney disease.
The company who makes daprodustat have informed NICE that they will not pursue a license for daprodustat from the UK MHRA. This appraisal will therefore be suspended.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- TA
- ID number:
- 3987
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- BMJ Technology Assessment Group (BMJ-TAG), BMJ
Stakeholders
- Companies sponsors
- GlaxoSmithKline (Jesduvroq,
- daprodustat)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- Polycystic Kidney Disease Charity
- Professional groups
- Anaemia Nurse Specialist Association
- Royal College of Physicians
- UK Kidney Association
- Assessment group
- Centre for Reviews and Dissemination and Centre for Health Economics, University of York
- Comparator companies
- Amgen (darbepoetin alfa) (no CA&U signed, not participating)
- Pfizer (epoetin zeta) (no CA&U signed, not participating)
- Janssen (epoetin alfa) (no CA&U signed, not participating)
- Roche (epoetin beta, methoxy polyethylene glycol-epoetin beta) (no CA&U signed, not participating)
- Astellas Pharma Ltd (roxadustat) (CA&U signed, participating)
- General commentators
- All Wales Therapeutic and Toxicology Centre
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Healthcare Improvement Scotland
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 09 October 2023 | Suspended. The company who makes daprodustat have informed NICE that they will not pursue a license for daprodustat from the UK MHRA. This appraisal will therefore be suspended. |
| 22 August 2022 | The company, GlaxoSmithKline, has been in touch with NICE to request a delay to the submission. As a consequence, the appraisal committee discussion originally scheduled for 8 February 2023 has been cancelled. A new Committee meeting date has been scheduled for 5 April 2023. The deadline for evidence submission is now 5pm on 6 October 2022 and we anticipate that technical engagement will be in mid-January 2023. Further updates will be available in due course. |
| 15 June 2022 | Invitation to participate |
| 28 January 2022 - 25 February 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 24 November 2021 | In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual